Lumanu, Doyenne Group, Intellivisit & More: This Week’s WI Watchlist
(Page 2 of 2)
and could one day become a drug developer itself, has inked multiple partnership agreements in recent months. Under the terms of the latest deal, with the Australia-based QIMR Berghofer Medical Research Institute, Invenra will develop antibodies designed to bind to a target that QIMR Berghofer has identified.
—One of Invenra’s co-founders, Emile Nuwaysir, was recently named CEO of BlueRock Therapeutics, which is based in Cambridge, MA. One of BlueRock’s projects involves developing cell therapies that would allow patients who have had a heart attack to regenerate heart muscle. Until last month, Nuwaysir had served as president and chief operating officer at Madison-based Cellular Dynamics International.